Parameters HCV patients
with HCC
(n=15)
HCV patients
without HCC
(n=15)
Healthy
Subjects
(n=15)
P value
Age (years) 51.27 ± 5.56 52.73 ± 7.23 50.93 ± 6.77 0.844
Gender:
- Male (%)
- Female (%)
15 (100.0)
0 (0.0)
15 (100.0)
0 (0.0)
15 (100.0)
0 (0.0)
 
AST  (U/L; mean ± SD) 68.40  ± 30.38a b 50.87 ± 25.11a 20.13 ± 3.78 <0.0001
ALT (U/L; mean ± SD) 71.47 ± 29.44a b 40.53 ± 19.18a 20.40 ± 4.55 <0.0001
GGT (U/L; mean ± SD) 102.27 ±  80.4 a b 43.47 ± 21.62 20.93 ± 3.20 0.0001
Serum albumin (g/dl; mean ± SD) 3.53 ± 0.20a 3.49 ± 0.18a 4.60 ± 0.46 <0.0001
Serum bilirubin (mg/dl; mean ± SD) 1.08 ± 0.13 a 1.05 ± 0.23 a 0.64 ± 0.16 <0.0001
INR (mean ± SD) 1.19 ±  0.08 a 1.25 ± 0.13 a 1.07 ± 0.04 <0.0001
AFP (ng/ml; mean ± SD) 1302.36 ± 1890.19a b 6.00 ± 2.35 4.60 ±1.60 0.002
Child-Pugh class:
- Class A (%)
- Class B (%)
11 (73.3)
4 (26.7)
7 (46.7)
8 (53.3)
NA 0.132
MELD score 7.13 ± 1.19 8.40 ± 1.96 NA 0.119
Serum MIP-1a (pg/ml) 27.33 ± 4.58a b 8.67 ± 6.11a 1.67 ± 2.44 <0.0001
AST: Aspartate Amino Transferase; ALT: Alanine Amino Transferase; GGT: Gamma Glutamyl Transpeptidase; INR: International Normalized Ratio; AFP: Alpha-Fetoprotein; MELD: Model for End-Stage Liver Disease; MIP-1α: Macrophage Inflammatory Protein-1α
NA=not applicable
a=Statistically-significant difference from healthy subject;
b=Statistically-significant difference from cirrhotic patients without HCC.
Table 1: Clinical and biochemical characteristics of HCV-related cirrhotic patients with and without Hepatocellular Carcinoma (HCC) and healthy subjects.